WASHINGTON, DC, Oct. 3 – Clairus Technologies said that it is set to sign a letter of intent with an Ivy League university in the US to collaborate research on certain genomic-based diagnostic products, a company official said on Wednesday.
Gregory Sullivan, senior vice president of business development and marketing at Clairus, told GenomeWeb that the partnership should be finalized in the current quarter. He spoke outside the Biotechnology Industry Organization Venture Forum meeting here, which runs through Thursday.
The deal centers on technology developed at the university, which was not named, that detects the origin of a variety of inflammatory responses, including those that cause asthma and inflammatory bowel disease, Sullivan said.
Clairus, based in Rockville, Md., links research efforts of its own laboratory with those of academic centers, the government, or industry as a way to fatten resources for tool invention and diagnostic- and drug-discovery.